Evaluation of HEArt invoLvement in Patients With FABRY Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorWuerzburg University Hospital
About this trial
This study evaluates predictors for the incidence of arrhythmias and sudden cardiac death as well as terminal heart failure in patients with Fabry disease.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Fabry disease (genetically confirmed)
Signed informed consent
18 years and older
Disqualifiers
No informed consent
Withdrawal of informed consent
Trial population
The study population includes every patient with Fabry disease who is seen in the FAZiT Wuerzburg. No limitations are made.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Cardiac death
Patients sustaining cardiac death
Time frame
From date of inclusion until the date of first documented event, up to the year 2032Secondary outcomes
1
Heart transplantation
On the basis of severe cardiac damage heart transplantation is needed
Time frame
From date of inclusion until the date of first documented event, up to the year 20322
Malign Arrhythmias
Patients suffering any malign arrhythmias
Time frame
From date of inclusion until the date of death, up to the year 2032Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Wuerzburg University Hospital
Lead sponsor
Competence Network Heart Failure
Collaborator
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborator
St George's, University of London
Collaborator
Source ClinicalTrials.gov